0001697532 false 0001697532 2023-06-06 2023-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): June 6, 2023 (June 6, 2023

 

APPLIED THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38898   81-3405262
(State or Other Jurisdiction of
Incorporation)
  (Commission File Number)   (I.R.S. Employer Identification No.)

 

545 Fifth Avenue, Suite 1400
New York, NY 10017
10017
(Address of Principal Executive Offices) (Zip Code)

 

Registrant’s telephone number, including area code:  (212) 220-9226

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which
registered
Common Stock   APLT   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company               x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.      x

 

 

 

 

 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

At the 2023 Annual Meeting of Stockholders (the “Annual Meeting”) held on June 6, 2023, the stockholders of Applied Therapeutics, Inc. (the “Company”) voted on the matters described below.

 

1.The Company’s stockholders elected two Class I directors, who comprise all the directors of such class, to serve until the 2026 Annual Meeting of Stockholders and until his/her successor is duly elected and qualified or until his/her earlier death, resignation or removal.  The numbers of shares that voted for the election of such directors, withheld authority to vote for such directors and represented broker non-votes with respect to this proposal are summarized in the table below.

 

Director Nominee

 

Votes For

 

Votes Withheld

 

Broker Non-Votes

Les Funtleyder   22,599,062   6,982,408   6,499,766  
Stacy J. Kanter   23,636,835   5,944,635   6,499,766  

 

2.The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.  The numbers of shares that voted for, against and abstained from voting for or against the ratification of the appointment of Ernst & Young LLP are summarized in the table below.

 

Votes For

 

Votes Against

 

Abstentions

35,864,793   205,113   11,330

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  APPLIED THERAPEUTICS, INC.
     
Dated: June 6, 2023 By: /s/ Shoshana Shendelman
  Name: Shoshana Shendelman
  Title: President and Chief Executive Officer